CytomX Therapeutics Hits Day High with Strong 7.48% Intraday Surge

CytomX Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable uptick in its stock price, gaining 7.48% on March 9, 2026. The stock reached an intraday high of USD 5.05, reflecting a significant moment in its trading activity for the day. Despite this positive movement, the company has faced challenges in its financial performance. Over the past year, CytomX has shown a remarkable increase of 656.5%, significantly outperforming the S&P 500's 17.78% gain. However, its recent weekly and monthly performances have been less favorable, with declines of 5.81% and 11.75%, respectively. CytomX's financial metrics reveal a complex picture. The company reported a steep decline in net sales of 82.16%, with the latest quarterly net sales at USD 5.96 million. Additionally, the operating profit margin has dipped to -263.86%, indicating ongoing financial pressures. With a market capitalization of USD 920 million and a P/E ratio of 13.00, CytomX continues to navigate a challenging landscape in the biotechnology industry.